CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

计划入组 98 人 · 首次发布于 2023 年 12 月 27 日

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

计划入组 1,012 人 · 首次发布于 2020 年 7 月 30 日

Bortezomib in Intrahepatic Cholangiocellular Carcinoma

计划入组 50 人 · 首次发布于 2017 年 11 月 17 日

INGN-251

PTEN mRNA nanoparticles(Harvard University)

CDKL5 deficiency disorder therapeutic program (Vyant Bio Inc/Cyclica Inc)

Rockwell Medical

United States

Ai-Media Technologies Ltd

United States

ENDOFOTONICS PTE. LTD.

Singapore

Capivasertib Shows Significant Survival Benefit in PTEN-Deficient Metastatic Prostate Cancer

Capivasertib Plus Abiraterone Extends Radiographic Progression-Free Survival in PTEN-Deficient mHSPC

Truqap plus Abiraterone and ADT Improves rPFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer